Skip to content
ADMETatlas
peptide evidence atlas
Home
About
Home

Browse

PeptidesProductsEvidenceContext signalsDescriptors

Developability

ProfileComparator

Resources

ManualExplanationsStatisticsDownloadLicenseAbout
  1. Home
  2. Peptides
  3. Degarelix
Peptide·plain sequence-like

Degarelix

ATLPC0025050

Routes
Compare in workbenchDownload releaseAPI JSON
On this page
  • 01 Sequence & molecular identity
  • 02 Physicochemical profile
  • 03 Exposure / Absorption
  • 04 Distribution / Barrier
  • 05 Excretion / Persistence
  • 06 Evidence landscape
  • 07 Product context
  • 08 Identity & reference map
  • 09 Data access & reproducibility
Coveragecounts only · not riskATLPC0025050
  • Measurements
    9
  • Endpoints
    7
  • Domains
    3/5
  • Products
    1
  • No matrix stability evidence
  • 1 clearance measurement
  • Product-level review pending
  • No sequence liability cues
Jump to domain

Open the matching evidence section below

All evidence index · 9
Exposure / Absorption
5 measurements
Distribution / Barrier
3 measurements
Metabolic & Proteolytic Stability
No evidence
Excretion / Persistence
1 measurement
Toxicity / Safety
No evidence
01

Sequence & molecular identity

1 forms

Reviewed sequence, peptidoform forms, chemical representation, 3D references, and covalent topology used to interpret this peptide identity.

No reviewed sequence representation available

This peptide currently has identity-level evidence, but no reviewed sequence, HELM, or SMILES representation for residue-level interpretation.

Structure & chemistry

·
Chemical representationnone
Representation class

How the current release can interpret this identity chemically.

plain sequence-like
Parent-residue sequence

Residue string used for positional interpretation when available.

Not available
HELM

Polymer notation for modified peptide representation when available.

Not available
SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available
No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure referencesnone attached
3D structure not available

A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.

Covalent topology & modificationsnone
Exact topology not established

No reviewed form-level topology or residue-level connection annotation is attached to this peptide in the current release. This is not evidence that every molecular form is linear or unmodified.

02

Physicochemical profile

Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.

Physicochemical descriptors unavailable

These descriptors require a standard parent-residue sequence. The module remains visible so modified or unresolved identities are not forced into unreliable computed values.

03

Exposure / Absorption

5 records

What evidence describes systemic exposure or absorption?

Evidence records
5
Complete canonical measurements and observations attached to this domain.
Endpoint scope
4
Formal ADMET endpoints represented for this peptide.
Matched-context analysis
2
Quantitative results that may be analysed only with scientifically compatible records.
Reported-result review
3
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopeBioavailabilityAUCTmaxCmax
Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis
Quantitative results whose endpoint and context must still be matched before analysis.
2
Interpret as reported
Qualitative, narrative, or review-first findings preserved in source context.
3
Supporting context only
Reference, label, clinical, or supporting context for interpretation.
0
Review before analysis
Records whose present structure does not establish a safe analysis role.
0
Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

·
Bioavailability2 records · 2 matched-context · 0 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

~ 60 %

Eligible when experimental context matches

TGA Product Information 5.2 pharmacokinetic properties manual extraction · human · plasma

Result: Approximate quantitative measurement · Molecular form: ATLPF0032390 · Route: subcutaneous · Dose/window: FIRMAGON 20 mg/mL dose concentration · Source: Primary reference linked

Reference
2

~ 40 %

Eligible when experimental context matches

TGA Product Information 5.2 pharmacokinetic properties manual extraction · human · plasma

Result: Approximate quantitative measurement · Molecular form: ATLPF0032390 · Route: subcutaneous · Dose/window: FIRMAGON 40 mg/mL dose concentration · Source: Primary reference linked

Reference
AUC1 record · 0 matched-context · 1 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

1054 ng*d/mL

Use only explicitly reported fields

human

Result: Reported point value · Molecular form: ATLPF0032390 · Degarelix· 12.3 Pharmacokinetics · degarelix mean auc sc 240mg · Following administration... · Source: Primary reference linked

Reference
Cmax1 record · 0 matched-context · 1 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

26.2 ng/mL

Use only explicitly reported fields

human

Result: Reported point value · Molecular form: ATLPF0032390 · Degarelix· 12.3 Pharmacokinetics · cmax was value · Following administration of FIRMAGON... · Source: Primary reference linked

Reference
Tmax1 record · 0 matched-context · 1 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

<= 2 days

<= 172800 seconds
Interpret as reported

human

Result: Upper-bound measurement · Molecular form: ATLPF0032390 · Route: subcutaneous · Degarelix· 12.3 Pharmacokinetics · degarelix tmax cmax occurred within time · Typically C... · Source: Primary reference linked

Reference
04

Distribution / Barrier

3 records

What is known about distribution, binding, permeability, or barrier crossing?

Evidence records
3
Complete canonical measurements and observations attached to this domain.
Endpoint scope
2
Formal ADMET endpoints represented for this peptide.
Matched-context analysis
0
Quantitative results that may be analysed only with scientifically compatible records.
Reported-result review
3
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopeVdPlasma protein binding
Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis
Quantitative results whose endpoint and context must still be matched before analysis.
0
Interpret as reported
Qualitative, narrative, or review-first findings preserved in source context.
3
Supporting context only
Reference, label, clinical, or supporting context for interpretation.
0
Review before analysis
Records whose present structure does not establish a safe analysis role.
0
Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

·
Vd2 records · 0 matched-context · 2 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

> 1 L/kg

Interpret as reported

human

Result: Lower-bound measurement · Molecular form: ATLPF0032390 · Route: intravenous · Degarelix· 12.3 Pharmacokinetics · degarelix volume of distribution iv · Distribution The... · Source: Primary reference linked

Reference
2

> 1000 L

Interpret as reported

human

Result: Lower-bound measurement · Molecular form: ATLPF0032390 · Route: subcutaneous · Degarelix· 12.3 Pharmacokinetics · degarelix volume of distribution sc · Distribution The... · Source: Primary reference linked

Reference
Plasma protein binding1 record · 0 matched-context · 1 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

90 %

Use only explicitly reported fields

human · plasma

Result: Reported point value · Molecular form: ATLPF0032390 · Degarelix· 12.3 Pharmacokinetics · plasma protein binding percent · In vitro plasma prote... · Source: Primary reference linked

Reference
Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA
0

artificial membrane

Caco-2
0

cell monolayer

MDCK
0

cell monolayer

RRCK
0

cell monolayer

BBB
0

barrier evidence

05

Excretion / Persistence

1 records

What evidence describes clearance or persistence?

Evidence records
1
Complete canonical measurements and observations attached to this domain.
Endpoint scope
1
Formal ADMET endpoints represented for this peptide.
Matched-context analysis
0
Quantitative results that may be analysed only with scientifically compatible records.
Reported-result review
1
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopeClearance
Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis
Quantitative results whose endpoint and context must still be matched before analysis.
0
Interpret as reported
Qualitative, narrative, or review-first findings preserved in source context.
1
Supporting context only
Reference, label, clinical, or supporting context for interpretation.
0
Review before analysis
Records whose present structure does not establish a safe analysis role.
0
Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

·
Clearance1 record · 0 matched-context · 1 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

~ 9 L/h

Use only explicitly reported fields

human

Result: Approximate quantitative measurement · Molecular form: ATLPF0032390 · Route: subcutaneous · Degarelix· 12.3 Pharmacokinetics · clearance single · Following subcutaneous administrati... · Source: Primary reference linked

Reference
06

Evidence landscape

9 records

Cross-domain evidence distribution and measurement-level detail; the domain modules above show evidence in context, and every row remains available for audit here.

Evidence landscape

A cross-domain view of evidence volume, scientifically permitted analysis use, and source traceability.

ADMET domain
Eligible when context matches
Interpret as reported
Supporting context only
Review before analysis
Exposure / Absorption
5 evidence records
2
3
0
0
Distribution / Barrier
3 evidence records
0
3
0
0
Metabolic & Proteolytic Stability
0 evidence records
0
0
0
0
Excretion / Persistence
1 evidence record
0
1
0
0
Toxicity / Safety
0 evidence records
0
0
0
0
Endpoint distribution

Top evidence-bearing endpoint questions.

Bioavailability
2
Volume Of Distribution
2
Area Under Curve
1
Clearance
1
Max Concentration
1
Plasma Protein Binding
1
Time To Max Concentration
1
Assay context

Broad context buckets, useful before comparing values.

In vivo / route
9
Traceability

Reference-link availability for measurement-level audit.

Linked reference
9
Not linked
0
All evidence index

Every evidence record remains available for audit and drilldown. Counts describe evidence volume, not confidence.

#ADMET domainEndpointReported valueResult typeAnalysis useAssay / modelConditionReference
1
Exposure / Absorption
Exposure
Bioavailability
~ 60 %
Approximate quantitative measurementEligible when experimental context matchesTGA Product Information 5.2 pharmacokinetic properties manual extraction · human · plasmaRoute: subcutaneous · Dose/window: FIRMAGON 20 mg/mL dose concentration · Population pharmacokinetic model estimate for the registered maintenance-dose concentration.
Reference
Primary reference linked
2
Exposure / Absorption
Exposure
Bioavailability
~ 40 %
Approximate quantitative measurementEligible when experimental context matchesTGA Product Information 5.2 pharmacokinetic properties manual extraction · human · plasmaRoute: subcutaneous · Dose/window: FIRMAGON 40 mg/mL dose concentration · Population pharmacokinetic model estimate for the registered starting-dose concentration.
Reference
Primary reference linked
3
Exposure / Absorption
Exposure
Area Under Curve
1,054 ng*d/mL
Reported point valueUse only explicitly reported fieldshumanNot specified
Reference
Primary reference linked
4
Exposure / Absorption
Exposure
Time To Max Concentration
<= 2 days
<= 172,800 seconds
Upper-bound measurementInterpret as reportedhumanRoute: subcutaneous
Reference
Primary reference linked
5
Distribution / Barrier
Distribution
Volume Of Distribution
> 1 L/kg
Lower-bound measurementInterpret as reportedhumanRoute: intravenous
Reference
Primary reference linked
6
Distribution / Barrier
Distribution
Volume Of Distribution
> 1,000 L
Lower-bound measurementInterpret as reportedhumanRoute: subcutaneous
Reference
Primary reference linked
7
Exposure / Absorption
Exposure
Max Concentration
26.2 ng/mL
Reported point valueUse only explicitly reported fieldshumanNot specified
Reference
Primary reference linked
8
Distribution / Barrier
Distribution
Plasma Protein Binding
90 %
Reported point valueUse only explicitly reported fieldshuman · plasmaNot specified
Reference
Primary reference linked
9
Excretion / Persistence
Persistence
Clearance
~ 9 L/h
Approximate quantitative measurementUse only explicitly reported fieldshumanRoute: subcutaneous
Reference
Primary reference linked
1–9 / 9
07

Product context

1 products

Product-level route, label, and clinical context that frames peptide-level evidence. A peptide-level summary only; product pages keep the full drilldown.

·
Summary1 linked product
Linked products
1
Label context
None
Clinical trials
40
Safety label cues
None
Linked products1 shown

Degarelix

Peptide-product match
Reviewed peptide match
Route / product class
subcutaneous · Injection, powder
Clinical context
40 trial records · 23 exact intervention matches · 8 with results · latest 2026-04-20
Label safety context
No label safety cue linked
View product
08

Identity & reference map

9 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

·
Summary2 reference groups
Identity type
identity record
Reported notation
0
Reference groups
2
Measurements
9
ATL peptide ID
ATLPC0025050
Identity concordance
Identity concordance
Exact reported notation

Reported sequence string matches the current peptide notation.

0 / 9
Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 9
Different notation

Reported notation does not resolve to the current display sequence.

0 / 9
Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

9 / 9
Reported sequence notation

No source-specific sequence notation has been captured in the current identity references.

Current identity
No sequence representation
Reported names
No distinct human-readable aliases are exposed.
Reference map2 reference groups
Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

ReferenceSupportsReported identityRecords
Reference
Open
DistributionExposurePersistence
Area Under Curve, Clearance, Max Concentration, Plasma Protein Binding +2 more
No reported alias
7 identity
7 evidence
Reference
Open
Exposure
Bioavailability
No reported alias
2 identity
2 evidence
09

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

·
Record scopePublic release
ATL peptide ID
ATLPC0025050
Identity type
identity record
ADMET endpoints
7
Evidence records
9
Reference groups
2
Release view
Public release
Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Open JSON

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements
Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

Open endpoint
GET /api/v1/peptides/ATLPC0025050
open
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0025050' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'
ADMETatlas
peptide evidence atlas

ADMETatlas is an open, curated atlas of ADMET evidence for therapeutic peptides — spanning developability, membrane permeability and blood–brain-barrier transport, immune-recognition context, and approved-product context. Every measurement stays linked to its original source, with stable identifiers and transparent curation, so results can be traced, cited, and reproduced.

Browse
PeptidesProductsEvidenceContext signalsDescriptors
Resource
DevelopabilityComparatorManualExplanationsStatisticsDownloadAbout
Stack
  • RDKit
  • Mol*
  • Python
  • FastAPI
  • PostgreSQL
  • Next.js
  • React
  • TypeScript
  • Tailwind CSS
  • Apache ECharts
© 2026 ADMETatlas, an academic peptide ADMET evidence atlas.